School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, 529020, China.
Neurosurgery Department, Jiangmen Wuyi Hosipital of TCM, Affiliated Jiangmen TCM Hospital of Ji'nan University, Jiangmen, 529020, China.
J Biomed Nanotechnol. 2021 Dec 1;17(12):2455-2465. doi: 10.1166/jbn.2021.3204.
This research was performed to optimize the enzymatic synthesis of mannosylated ligand with which to prepare mannosy-lated liposomes and investigate their bioactivity. Based on single-factor studies, lipase dose, substrate molar ratio (diester lauric diacid-cholesterol to mannose) and temperature were identified as significant parameters, and optimal reaction conditions were determined through response surface methodology (RSM) with central composite design. The optimum operating parameters, 61.23 mg of lipase, a substrate molar ratio of 5.36, and 56.64 °C temperature offered a predicted yield (71.11%) which was consistent with the actual yield (69.08%). Drug-free mannosylated liposomes were prepared film-dispersion. The characterizations of these liposomes showed that mannosylated liposomes were well-dispersible spherical particles with an average particle size of 142.3 nm, the polydispersity index of 0.16, and a zeta potential of -19.8 mV. Pyrogen examination, hemolytic studies and cytotoxicity assays revealed no substantial safety concern for drug-free mannosylated liposomes. Cellular uptake efficiency of mannosylated liposomes by HepG2 cells was significantly higher than that of unmodified liposomes, demonstrating that mannosylated ligands have a positive effect on liver targeting. Overall, mannosylated liposomes could be active drug delivery system for combatting the therapy of hepatic diseases.
本研究旨在优化酶法合成甘露糖配体,用于制备甘露糖化脂质体并研究其生物活性。基于单因素研究,确定了脂肪酶剂量、底物摩尔比(二酯月桂二酸-胆固醇与甘露糖)和温度是显著参数,并通过中心复合设计的响应面法(RSM)确定了最佳反应条件。最佳操作参数为 61.23mg 脂肪酶、底物摩尔比为 5.36 和 56.64°C 温度,预测产率(71.11%)与实际产率(69.08%)一致。制备了无药物甘露糖化脂质体。这些脂质体的特性表明,甘露糖化脂质体是良好分散的球形颗粒,平均粒径为 142.3nm,多分散指数为 0.16,zeta 电位为-19.8mV。热原检查、溶血研究和细胞毒性试验表明,无药物甘露糖化脂质体没有明显的安全性问题。甘露糖化脂质体被 HepG2 细胞摄取的效率明显高于未修饰的脂质体,表明甘露糖配体对肝靶向具有积极作用。总的来说,甘露糖化脂质体可以作为一种有效的药物传递系统,用于治疗肝脏疾病。